Wedbush Issues Optimistic Outlook for BCRX Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Wedbush boosted their Q1 2026 earnings per share estimates for BioCryst Pharmaceuticals in a research note issued on Monday, June 30th. Wedbush analyst L. Chico now expects that the biotechnology company will post earnings of $0.18 per share for the quarter, up from their prior forecast of $0.11. Wedbush currently has a "Outperform" rating and a $18.00 price target on the stock. The consensus estimate for BioCryst Pharmaceuticals' current full-year earnings is ($0.36) per share. Wedbush also issued estimates for BioCryst Pharmaceuticals' Q4 2026 earnings at $0.25 EPS, FY2027 earnings at $0.79 EPS and FY2029 earnings at $1.07 EPS.

Other analysts also recently issued reports about the stock. HC Wainwright reissued a "buy" rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. Wall Street Zen lowered shares of BioCryst Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, June 28th. Cantor Fitzgerald assumed coverage on BioCryst Pharmaceuticals in a research report on Tuesday, April 29th. They set an "overweight" rating and a $20.00 target price on the stock. Barclays upped their price target on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an "equal weight" rating in a report on Wednesday, May 7th. Finally, Royal Bank Of Canada reiterated an "outperform" rating and set a $13.00 price target on shares of BioCryst Pharmaceuticals in a research report on Monday, June 30th. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, BioCryst Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $16.70.

BioCryst Pharmaceuticals Trading Down 0.8%

BioCryst Pharmaceuticals stock traded down $0.08 during mid-day trading on Wednesday, hitting $8.95. The company had a trading volume of 1,407,127 shares, compared to its average volume of 3,039,076. The company has a market capitalization of $1.87 billion, a price-to-earnings ratio of -34.40, a P/E/G ratio of 2.55 and a beta of 1.04. BioCryst Pharmaceuticals has a 12-month low of $6.02 and a 12-month high of $11.31. The company's fifty day moving average is $10.06 and its 200-day moving average is $8.60.

Institutional Trading of BioCryst Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Doliver Advisors LP boosted its stake in BioCryst Pharmaceuticals by 269.1% during the 2nd quarter. Doliver Advisors LP now owns 274,328 shares of the biotechnology company's stock worth $2,458,000 after purchasing an additional 200,000 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of BioCryst Pharmaceuticals by 3.9% in the first quarter. Rhumbline Advisers now owns 321,154 shares of the biotechnology company's stock worth $2,409,000 after buying an additional 12,022 shares in the last quarter. Strs Ohio acquired a new position in BioCryst Pharmaceuticals during the first quarter worth about $284,000. Acadian Asset Management LLC grew its stake in BioCryst Pharmaceuticals by 244.1% during the 1st quarter. Acadian Asset Management LLC now owns 670,361 shares of the biotechnology company's stock valued at $5,023,000 after acquiring an additional 475,564 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in BioCryst Pharmaceuticals by 11.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,466 shares of the biotechnology company's stock valued at $3,363,000 after acquiring an additional 47,355 shares in the last quarter. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.